[go: up one dir, main page]

WO2015068142A3 - Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder - Google Patents

Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder Download PDF

Info

Publication number
WO2015068142A3
WO2015068142A3 PCT/IB2014/065924 IB2014065924W WO2015068142A3 WO 2015068142 A3 WO2015068142 A3 WO 2015068142A3 IB 2014065924 W IB2014065924 W IB 2014065924W WO 2015068142 A3 WO2015068142 A3 WO 2015068142A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloproliferative disorder
compositions
jak2
composition
dominant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/065924
Other languages
French (fr)
Other versions
WO2015068142A2 (en
Inventor
Ansu KUMAR
Neeraj Kumar SINGH
Anuj Tyagi
Shireen VALI
Taher ABBASI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Works Group Inc
Original Assignee
Cell Works Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Works Group Inc filed Critical Cell Works Group Inc
Publication of WO2015068142A2 publication Critical patent/WO2015068142A2/en
Publication of WO2015068142A3 publication Critical patent/WO2015068142A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to a pharmaceutical composition and a method to manage Myeloproliferative disorder or any associated condition, particularly, JAK2 (Janus Kinase 2) dominant (including JAK2V617F mutant) Myeloproliferative Disorder (MPD) and associated conditions. The disclosure provides composition comprising at least two components selected from a group comprising Phosphodiesterase Type 4 (PDE4) inhibitor, Autophagy inhibitor and AMPK agonist. The disclosure further relates to a process of preparing the said composition and a method of managing JAK2 dominant (including JAK2 V617F mutant) Myeloproliferative Disorder; existing alone or along with any other mutation.
PCT/IB2014/065924 2013-11-11 2014-11-10 Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder Ceased WO2015068142A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN5103/CHE/2013 2013-11-11
IN5103CH2013 2013-11-11
IN4949CH2014 2014-10-01
IN4949/CHE/2014 2014-10-01

Publications (2)

Publication Number Publication Date
WO2015068142A2 WO2015068142A2 (en) 2015-05-14
WO2015068142A3 true WO2015068142A3 (en) 2015-09-24

Family

ID=52014184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/065924 Ceased WO2015068142A2 (en) 2013-11-11 2014-11-10 Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder

Country Status (1)

Country Link
WO (1) WO2015068142A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055705A1 (en) * 2019-09-18 2021-03-25 The Regents Of The University Of California Biaminoquinolines and nanoformulations for cancer treatment
CN110917406A (en) * 2019-12-06 2020-03-27 段传志 Artificial blood vessel stent and preparation method and application thereof
EP4188377B8 (en) * 2021-03-23 2024-04-03 Cellworks Group Inc. Combination comprising chloroquine, metformin and statin for management of cancer, composition and methods thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060313A2 (en) * 2002-12-30 2004-07-22 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
WO2011100319A1 (en) * 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
US20130156865A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060313A2 (en) * 2002-12-30 2004-07-22 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
WO2011100319A1 (en) * 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2012171015A2 (en) * 2011-06-10 2012-12-13 Translational Genomics Research Institute Therapeutic combination for cancer treatment
US20130156865A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPH MAACK ET AL: "Abstract 763: Human Cardiac Beta1-Adrenergic Receptors Are Desensitized By Receptor-Mediated Activation Of Phosphatidylinositol-3 Kinase and Phosphodiesterase-4 -- Maack et al. 116 (10016): II_146 -- Circulation", CIRCULATION 2007; 116(146), 1 January 2007 (2007-01-01), XP055162165, Retrieved from the Internet <URL:http://circ.ahajournals.org/cgi/content/meeting_abstract/116/16_MeetingAbstracts/II_146-c> [retrieved on 20150114] *
CHRISTOPHER J. GREGG ET AL: "[beta]2-Adrenergic Receptor-Coupled Phosphoinositide 3-Kinase Constrains cAMP-Dependent Increases in Cardiac Inotropy Through Phosphodiesterase 4 Activation", ANESTHESIA & ANALGESIA, 1 August 2010 (2010-08-01), pages 1, XP055162556, ISSN: 0003-2999, DOI: 10.1213/ANE.0b013e3181ee8312 *
E. VAKANA ET AL: "Antileukemic effects of AMPK activators on BCR-ABL-expressing cells", BLOOD, vol. 118, no. 24, 8 December 2011 (2011-12-08), pages 6399 - 6402, XP055162810, ISSN: 0006-4971, DOI: 10.1182/blood-2011-01-332783 *
G. MOLOSTVOV ET AL: "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures", BRITISH JOURNAL OF HAEMATOLOGY, vol. 124, no. 3, 1 February 2004 (2004-02-01), pages 366 - 375, XP055162553, ISSN: 0007-1048, DOI: 10.1046/j.1365-2141.2003.04777.x *

Also Published As

Publication number Publication date
WO2015068142A2 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
WO2015039612A8 (en) Compound inhibiting activities of btk and/or jak3 kinases
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2009011951A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2014151871A3 (en) Jak2 and alk2 inhibitors and methods for their use
TN2010000131A1 (en) Polo-like kinase inhibitors
MX347917B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof.
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
WO2007117995A3 (en) Kinase inhibitors
WO2012096887A3 (en) Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
WO2009142732A3 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
MX2012009074A (en) Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors.
EP4620528A3 (en) Bipyrazole derivatives as jak inhibitors
WO2011116356A3 (en) Positive allosteric modulators of group ii mglurs
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
WO2013185082A3 (en) Inhibitors of bruton&#39;s tyrosine kinase
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
MX379383B (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
MX2009011952A (en) Compounds and compositions as c-kit and pdgfr kinase inhibitors.
WO2009065922A3 (en) Organic compounds
HK1215166A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
WO2014016849A3 (en) Novel triazine compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14809119

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14809119

Country of ref document: EP

Kind code of ref document: A2